Charles River Laboratories International (NYSE:CRL) Price Target Cut to $166.00 by Analysts at Barclays

Charles River Laboratories International (NYSE:CRL) had its price objective trimmed by Barclays from $205.00 to $166.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the medical research company’s stock.

Other equities research analysts also recently issued reports about the stock. Bank of America lowered their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. The Goldman Sachs Group lowered their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. UBS Group reissued a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $197.64.

Charles River Laboratories International Price Performance

NYSE CRL opened at $154.63 on Tuesday. The company has a market cap of $7.91 billion, a PE ratio of 19.35, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. Charles River Laboratories International has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm’s 50-day simple moving average is $174.59 and its two-hundred day simple moving average is $189.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CRL. Virtu Financial LLC bought a new position in shares of Charles River Laboratories International in the third quarter worth approximately $601,000. JPMorgan Chase & Co. grew its holdings in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after purchasing an additional 85,759 shares during the last quarter. State Street Corp grew its holdings in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after purchasing an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International in the third quarter worth approximately $966,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).